Trial Profile
A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Jun 2018 Planned initiation date changed from 18 May 2018 to 18 Jul 2018.
- 05 Feb 2018 New trial record